Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease

Written by Lindsey Shapiro, PhD | Last updated Oct. 15, 2026
Fact-checked by Joana Carvalho, PhD

What is Lyfgenia for sickle cell disease?

Lyfgenia (lovotibeglogene autotemcel), previously known as lovo-cel or LentiGlobin, is a one-time gene therapy approved to treat adults and adolescents with sickle cell disease (SCD) who have a history of vaso-occlusive events (VOEs). The therapy is designed to reduce the frequency and severity of these events, which include painful vaso-occlusive crises (VOCs) and acute chest syndrome, as well as other sickle cell-related complications.

In SCD, a faulty version of hemoglobin — the protein that helps red blood cells carry oxygen — is produced due to mutations in the HBB gene. Abnormal hemoglobin causes red blood cells to take on a sickle-like shape, making them rigid, sticky, and more prone to getting stuck in blood vessels. This restricts blood flow and compromises oxygen transport, leading to VOEs.

Lyfgenia is a gene therapy for SCD that’s designed to provide patients with a modified HBB gene that produces a form of hemoglobin with anti-sickling properties. This enables red blood cells that carry the gene to resist sickling, resulting in fewer VOEs.

Treatment requires collecting a person’s own hematopoietic stem cells — precursors to all mature blood cells — and treating them in the lab with the modified gene. The cells are then returned to the body via a stem cell transplant, where the modified cells repopulate the blood with healthy hemoglobin-producing red blood cells.

Bluebird Bio markets Lyfgenia for SCD. The medication is administered via a single intravenous, or into-the-vein, infusion.

Therapy snapshot

Who can take Lyfgenia?

Lyfgenia is approved in the U.S. for the treatment of SCD patients, ages 12 and older, with a history of VOEs.

No contraindications are listed in Lyfgenia’s prescribing information. However, the therapy comes with a boxed warning noting that some patients who received treatment developed blood cancer. Those receiving the gene therapy should be on lifelong monitoring for such cancers.

How is Lyfgenia administered?

Lyfgenia is individually manufactured using a patient’s own cells. The entire treatment process involves several steps and must be conducted at a qualified treatment center with the expertise to administer the therapy.

Before treatment, healthcare providers will confirm that the patient is eligible for Lyfgenia, which requires a negative test for human immunodeficiency virus (HIV) types 1 and 2. Patients will also receive at least two cycles of blood transfusions. Some other SCD medications may need to be stopped in advance. Thereafter, the Lyfgenia treatment process involves:

• Stem cell mobilization and collection (about 1 week): Patients are treated with an injectable medication called plerixafor to move their stem cells out of the bone marrow and into the bloodstream. The cells are then collected from the blood in a process called apheresis, which may be repeated more than once if not enough cells are collected.
• Manufacturing (10 to 15 weeks): The cells are sent to the lab for modification, then shipped back to the healthcare provider.
• Myeloablative conditioning (4 days): At least two days before receiving Lyfgenia, patients receive a short course of high-dose chemotherapy with an agent called busulfan, which is infused into the bloodstream. This helps eliminate unhealthy blood stem cells and makes room for the new ones in the bone marrow.
• Lyfgenia administration (30 minutes to 2 hours): Lyfgenia is infused into the bloodstream at a weight-based dose. The minimum recommended dose is 3 million cells per kilogram of body weight.
• Recovery and monitoring (3 to 6 weeks): Patients stay in the treatment center for about 3-6 weeks for careful monitoring.

Lyfgenia in clinical trials

Lyfgenia’s approval was mainly supported by data from a group of 36 people with SCD who took part in the Phase 1/2 HGB-206 trial (NCT02140554). All had severe disease and had experienced at least four severe VOE events in the two years before giving informed consent to participate in the trial. All received the gene therapy.

Data from the now-complete study showed that:

• most participants were completely free of VOEs (88%) and severe VOEs (94%) between six months and 1.5 years after receiving Lyfgenia
• Lyfgenia treatment was associated with meaningful increases in hemoglobin levels, including the sickling-resistant version provided by the gene therapy, for most participants (86%)
• all five people who had previously experienced a stroke or related complication remained stroke-free for as long as five years of follow-up
• Lyfgenia was associated with reductions in pain and fatigue for more than half of the participants

An ongoing Phase 3 trial, HGB-210 (NCT04293185), is further evaluating the gene therapy in a similar patient population. Pooled data from both Lyfgenia clinical trials have shown that VOEs and severe VOEs were eliminated or significantly reduced in all participants over as long as five years.

Lyfgenia side effects

The most common side effects of Lyfgenia are:

• inflammation in the mucous membranes of the mouth (stomatitis)
• low blood cell counts

There have been few cases of blood cancer reported after Lyfgenia administration. According to the prescribing label, the increased risk of blood cancer could arise from cellular stress associated with stem cell mobilization, busulfan conditioning, or the Lyfgenia infusion. People with SCD are also at an increased risk of blood cancer compared with the general population.

Theoretically, Lyfgenia carries a risk of insertional oncogenesis. This means that if genetic material is inserted into a person’s DNA at unintended locations, it could cause gene activity changes that drive cancer-promoting cell growth.

Patients treated with Lyfgenia will be monitored for signs of cancer at least every six months, for a minimum of 15 years. An integration site analysis, which examines where genetic material has been inserted into the genetic code, should also be conducted at six months, one year, and as warranted.

Lyfgenia also carries warnings about other potentially serious side effects. Patients will be carefully monitored for these complications, which include:

• delayed recovery in levels of platelets, the cell fragments that help blood clot, which can increase the risk of bleeding
• a failure for white blood cell counts to rise after treatment, which increases the risk of infections
• immune reactions (hypersensitivity) during the infusion, including a life-threatening reaction called anaphylaxis

Certain medications might not be safe to take at various points in the Lyfgenia treatment process. It is important for patients to inform their healthcare team about all medications they are taking and to adhere to all medical guidance about how to take them.

Sickle Cell Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.